Brenton, James D.

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature

Breast Cancer Treatment StudiesCancer Genomics and Diagnostics

Cited by 6,097

Liquid biopsies come of age: Towards implementation of circulating tumour DNA

Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer

Cancer Genomics and DiagnosticsPrenatal Screening and Diagnostics

Cited by 2,809

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature

Cancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers

Cited by 1,624

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 1,196

Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE

Ovarian cancer diagnosis and treatmentCancer Cells and Metastasis

Cited by 403

Evolution of platinum resistance in high-grade serous ovarian cancer

Cooke, S. L., & Brenton, J. D. (2011) · The Lancet Oncology

Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancer

Cited by 213

Calibrating ensembles for scalable uncertainty quantification in deep learning-based medical image segmentation

Buddenkotte, T., Escudero Sanchez, L., Crispin-Ortuzar, M., Woitek, R., McCague, C., Brenton, J. D., Öktem, O., Sala, E., & Rundo, L. (2023) · Computers in Biology and Medicine

Medical Image Segmentation TechniquesAdvanced Neural Network Applications

Cited by 42

Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?

Funingana, I.-G., Reinius, M. A. V., Petrillo, A., Ang, J. E., & Brenton, J. D. (2021) · Seminars in Cancer Biology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 23

PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC)

Basu, B., Gourley, C., Gabra, H., Vergote, I. B., Brenton, J. D., Abrahmsen, L., Smith, A., Von Euler, M., & Green, J. A. (2016) · Annals of Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 8